RxDoctor Payments DataLook up a doctor →

Ansermo Arthur, MD

Interventional Cardiology · Aiken, SCNPI 1720161151

Payments from drug & device makers

$39,217in general payments, 2019–2025

Across 552 payments — averaging $71.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Abbott$5K
  • Pfizer$4K
  • Penumbra, Inc.$4K
  • Boston Scientific$2K
  • Cook Incorporated$2K
  • plus $11K from 48 others

What the payments were for

  • Speaking & faculty fees$14,18036%
  • Travel & lodging$12,31231%
  • Food & beverage$12,52832%
  • Education$1981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,217 in reported general payments places this provider in the 75th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$532,405
Medicare patients
1,541
Services billed
5,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,108$981,295
EntrestoSacubitril/Valsartan421$420,596
XareltoRivaroxaban384$323,029
BrilintaTicagrelor251$179,057
Droxidopa23$91,395
FarxigaDapagliflozin Propanediol78$72,242
JardianceEmpagliflozin37$36,220
VerquvoVericiguat11$18,729
EdarbiAzilsartan Medoxomil40$18,077
Repatha SureclickEvolocumab20$17,260
Valsartan440$11,886
Ranolazine ErRanolazine111$11,338
Dofetilide81$9,614
Metoprolol Succinate488$7,350
NexletolBempedoic Acid12$6,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,979$981,2951,108 claims
NovartisEntresto$653$420,596421 claims
Johnson & JohnsonXarelto$11,095$323,029384 claims
AstraZenecaBrilinta, Farxiga$398$251,299329 claims
Boehringer IngelheimJardiance$11$36,22037 claims
MerckVerquvo$211$18,72911 claims
Arbor Pharmaceuticals, Inc.Edarbi$60$18,07740 claims
Esperion Therapeutics, Inc.Nexletol$125$6,90412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →